natural alternative to glp-1 — Evidence‑backed options and practical plan Berberine is one of the

Despite these findings, a clear link has yet to be established, and much of the evidence remains inconsistent

New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.

Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive

By Michael S

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

COA included